beta-2--deoxythioguanosine and Remission--Spontaneous

beta-2--deoxythioguanosine has been researched along with Remission--Spontaneous* in 2 studies

Other Studies

2 other study(ies) available for beta-2--deoxythioguanosine and Remission--Spontaneous

Article	Year
Treatment of refractory adult acute leukemia with 5-azacytidine plus beta-2'-deoxythioguanosine. Cancer treatment reports, 1979, Volume: 63, Issue:2 Topics: Adolescent; Adult; Azacitidine; Deoxyguanosine; Drug Resistance; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Remission, Spontaneous; Thionucleosides; Time Factors	1979
Clinical studies of beta-thioguanine deoxyriboside alone and in combination with arabinosyl cytosine. Medical and pediatric oncology, 1976, Volume: 2, Issue:2 Beta-thioguanine deoxyriboside (betaTGdR) is a purine nucleoside derivative which was studied alone or in combination with arabinosyl cytosine (Ara-C) in patients with solid tumors and acute leukemia. No significant responses were observed in 22 patients with solid tumors. The response rate with betaTGdR alone in acute leukemia was 26% and in combination with Ara-C was 24%. Responses were generally of short duration. Toxicity included myelosuppression, nausea, stomatitis, hyperpigmentation, photosensitivity, and liver function abnormalities. Topics: Acute Disease; Adolescent; Adult; Aged; Child; Child, Preschool; Cytarabine; Deoxyguanosine; Deoxyribonucleosides; Drug Therapy, Combination; Female; Guanosine; Humans; Leukemia; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Remission, Spontaneous; Thioguanine; Thionucleosides; Thrombocytopenia; Time Factors	1976

Article

Year

Treatment of refractory adult acute leukemia with 5-azacytidine plus beta-2'-deoxythioguanosine.

Cancer treatment reports, 1979, Volume: 63, Issue:2

Topics: Adolescent; Adult; Azacitidine; Deoxyguanosine; Drug Resistance; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Remission, Spontaneous; Thionucleosides; Time Factors

1979

Clinical studies of beta-thioguanine deoxyriboside alone and in combination with arabinosyl cytosine.

Medical and pediatric oncology, 1976, Volume: 2, Issue:2

Beta-thioguanine deoxyriboside (betaTGdR) is a purine nucleoside derivative which was studied alone or in combination with arabinosyl cytosine (Ara-C) in patients with solid tumors and acute leukemia. No significant responses were observed in 22 patients with solid tumors. The response rate with betaTGdR alone in acute leukemia was 26% and in combination with Ara-C was 24%. Responses were generally of short duration. Toxicity included myelosuppression, nausea, stomatitis, hyperpigmentation, photosensitivity, and liver function abnormalities.

Topics: Acute Disease; Adolescent; Adult; Aged; Child; Child, Preschool; Cytarabine; Deoxyguanosine; Deoxyribonucleosides; Drug Therapy, Combination; Female; Guanosine; Humans; Leukemia; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Remission, Spontaneous; Thioguanine; Thionucleosides; Thrombocytopenia; Time Factors

1976